OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement ...
Pharmaceutical Technology on MSN10d
Opko and Entera focus on oral care for obesity and metabolic disordersOpko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral ...
The program combines OPKO's long-acting oxyntomodulin analog or OPK-88006 with Entera's proprietary N-Tab technology, and promising pharmacodynamic data has already been reported. The goal of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback